ArticleFrontiers in cardiovascular medicine2025
Expression levels of thymosin α1 in acute myocardial infarction patients and its correlation to cardiac function.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early prediction of heart failure (HF) after acute myocardial infarction (AMI) remains a clinical challenge. There is a lack of studies investigating Thymosin α1 expression levels in AMI patients and its relationship with cardiac function post-AMI. Methods: This retrospective analysis included patients with AMI from December 2019 to February 2022. The baseline data of two groups were collected. Thymosin α1 expression level of peripheral blood plasma in AMI patients was examined by ELISA. Logistic regression analysis was applied to evaluate risk factors in-hospital cardiac dysfunction after emergency PCI in AMI patients. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of the biomarker. Results: A total of 307 hospitalized patients were enrolled in this study, divided into AMI group ( Conclusion: Thymosin α1 may serve as a potential biomarker to predict cardiac function following AMI. This study may provide novel insights into the potential therapeutic targets for HF following AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.